Bio-Rad Purchases the Assets of Hematronix Inc. HERCULES, Calif., March 4 /PRNewswire-FirstCall/ -- Bio-Rad Laboratories, Inc. (Amex: BIO; BIOb), a multinational manufacturer and distributor of life science research products and clinical diagnostics, announced today that it has purchased the majority of assets of Hematronix Inc. of Plano, Texas. Bio- Rad will acquire the company's line of quality control products and services. Terms of the sale have not been disclosed. "This acquisition further enhances our leadership position in the area of quality control products that are integral to the accurate diagnosis of a wide variety of maladies," said Bio-Rad President and CEO Norman Schwartz. Bio-Rad will maintain Hematronix's operations in Plano, Texas, while research and development, manufacturing and distribution activities will continue in Benicia, California. Hematronix, Inc. is a private company that supplies quality control and quality assurance products and services to the clinical diagnostics industry. The company is a full line manufacturer of hematology and urine controls, hematology reagents and regulatory products and services. Bio-Rad offers a broad selection of quality control products that enable clinical laboratories to provide consistent and reliable patient testing results. Products include controls for hundreds of diagnostic analytes, sophisticated data management software and internet-based programs for quality control data reporting and comparative performance analysis. Bio-Rad Laboratories, Inc. (http://www.bio-rad.com/) is a multinational manufacturer and distributor of life science research products and clinical diagnostics. It is based in Hercules, California, and serves more than 70,000 research and industry customers worldwide through a network of more than 30 wholly owned subsidiary offices. Various statements made within this press release may constitute "forward- looking statements" for purposes of the Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. The forward- looking statements contained herein involve risks and uncertainties that could cause results to differ materially from the Company's expectations. DATASOURCE: Bio-Rad Laboratories, Inc. CONTACT: Susan Berg, Corporate Communications of Bio-Rad Laboratories, Inc., +1-510-741-6063, or Web site: http://www.bio-rad.com/

Copyright